NCT06235281 2026-02-27
PLIGHT
H. Lee Moffitt Cancer Center and Research Institute
Phase EARLY_PHASE1 Suspended
Clinical Trials
7 trialsNCT04541017 2025-10-16
Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment
National Cancer Institute (NCI)
Phase 1/2 Terminated
NCT04930653 2025-10-14
Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma
City of Hope Medical Center
Phase 2 Recruiting
NCT05414500 2025-08-08
Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides
University of Alabama at Birmingham
Phase 1 Recruiting
NCT04256018 2025-07-02
Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome
Stanford University
Phase 2 Recruiting
NCT04676087 2024-08-13
Mogamulizumab and Extracorporeal Photopheresis for the Treatment of Sezary Syndrome or Mycosis Fungoides
Emory University
Phase 1/2 Terminated
NCT04185220 2023-01-04
Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome
National Institutes of Health Clinical Center (CC)
Phase 1 Completed